Moderna COVID-19 vaccine

Moderna COVID-19 vaccine
	Vials of the Moderna COVID-19 vaccine
Vaccine description
Target	SARS-CoV-2
Vaccine type	mRNA
Clinical data
Trade names	Spikevax
Other names	mRNA-1273, CX-024414, COVID-19 mRNA Vaccine Moderna, TAK-919, Moderna COVID‑19 Vaccine, COVID‑19 Vaccine Moderna, COVID-19 Vaccine Moderna Intramuscular Injection, elasomeran, COVID-19 Vaccine (mRNA), davesomeran, imelasomeran, andusomeran, CX-034476, CX-038839
AHFS/Drugs.com	Monograph
MedlinePlus	a621002
License data	US DailyMed: Moderna COVID-19 Vaccine;
Pregnancy; category	AU: B1;
Routes of; administration	Intramuscular
ATC code	J07BN01 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); BR: Emergency use (COVAX); CA: ℞-only / Schedule D; UK: Marketing authorization granted; US: ℞-only with standing order; Spikevax approved for those aged 18+; Emergency Use Authorization for those aged six months and older; EU: Marketing authorization granted; Full list of Moderna vaccine authorizations;
Identifiers
CAS Number	2430046-03-8 ; 2798905-80-1;
PubChem SID	442064767;
DrugBank	DB15654; DB17091;
UNII	EPK39PL4R4; TYF7YW7ENF;
KEGG	D12114;
ChEMBL	ChEMBL4650491;

The Moderna COVID‑19 vaccine, sold under the brand name Spikevax, is a COVID-19 vaccine developed by the American company Moderna, the United States National Institute of Allergy and Infectious Diseases (NIAID), and the Biomedical Advanced Research and Development Authority (BARDA). Depending on the jurisdiction, it is authorized for use in humans aged six months, twelve years, or eighteen years and older. It provides protection against COVID-19, which is caused by infection by the SARS-CoV-2 virus. It is designed to be administered in two or three 0.5-mL doses given by intramuscular injection at an interval of at least 28 days apart.

It is an mRNA vaccine composed of nucleoside-modified mRNA (modRNA) encoding a spike protein of SARS-CoV-2, which is encapsulated in lipid nanoparticles.

It is authorized for use at some level in many countries.

In August and September 2022, bivalent versions of the vaccine (Moderna COVID-19 Vaccine, Bivalent) containing elasomeran/elasomeran 0-omicron (Spikevax Bivalent Zero/Omicron) were authorized for use as booster doses in individuals aged 18 years of age or older in the United Kingdom, Switzerland, Australia, Canada, the European Union, and the United States. The second component of the version of the bivalent vaccine used in the United States (mRNA-1273.222) is based on the Omicron BA.4/BA.5 variant, while the second component of the bivalent vaccine version used in other countries (mRNA-1273.214) is based on the Omicron BA.1 variant.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.